Search
Immix Biopharma Inc
IMMXAdd to Watchlist
10.340USD
+0.510+5.19%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
547.51MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.19%
5 Days
+6.38%
1 Month
+23.61%
6 Months
+90.42%
Year to Date
+97.71%
1 Year
+329.05%
Key Figures
9.870Open
10.455High
2.07MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.92%Turnover Ratio
9.830Prev. Close
9.740Low
15.51MTurnover
LossP/E Static
5.84P/B
0.00%Div Yield TTM
-60.47%ROA
11.61052wk High
1.30Volume Ratio
-21.61MNet Profit
52.95MShares
-0.9222EPS TTM
0.10Beta
-74.47%ROE
1.87052wk Low
7.27%Amplitude
--Gross Margin
547.51MMarket Cap
3.09Reward/Risk
5.34%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
Immix Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immix Biopharma Inc Info
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Ticker SymbolIMMX
CompanyImmix Biopharma Inc
CEORachman (Ilya)
Websitehttps://immixbio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52987.200
+144.700 (+0.27%)
29562.300
+250.900 (+0.86%)
7502.600
+31.100 (+0.42%)
15105.000
+302.000 (+2.04%)
69511.000
+1363.000 (+2.00%)
6377.400
+24.600 (+0.39%)
68.923
+0.579 (+0.85%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4176.990
+55.080 (+1.34%)
FAQs
What is the current price of Immix Biopharma Inc (IMMX)?
The current price of Immix Biopharma Inc (IMMX) is 10.34.
What is the symbol of Immix Biopharma Inc?
The ticker symbol of Immix Biopharma Inc is IMMX.
What is the 52-week high of Immix Biopharma Inc?
The 52-week high of Immix Biopharma Inc is 11.61.
What is the 52-week low of Immix Biopharma Inc?
The 52-week low of Immix Biopharma Inc is 1.87.
What is the market capitalization of Immix Biopharma Inc?
The market capitalization of Immix Biopharma Inc is 547.51M.
Is Immix Biopharma Inc (IMMX) currently rated as Buy, Hold, or Sell?
According to analysts, Immix Biopharma Inc (IMMX) has an overall rating of Buy, with a price target of 20.67.
What is the Earnings Per Share (EPS TTM) of Immix Biopharma Inc (IMMX)?
The Earnings Per Share (EPS TTM) of Immix Biopharma Inc (IMMX) is -0.89.